EQT's Galderma Says Nemolizumab Benefits Rare Skin Disease Patients in Late-stage Trial
© MT Newswires 2022
All news about EQT AB (PUBL) |
|
|
|
Analyst Recommendations on EQT AB (PUBL) |
|
|
| |
|
Sales 2021 |
1 461 M
1 486 M
1 486 M
|
Net income 2021 |
796 M
810 M
810 M
|
Net cash 2021 |
628 M
639 M
639 M
|
P/E ratio 2021 |
31,2x |
Yield 2021 |
1,51% |
|
Capitalization |
25 048 M
25 474 M
25 474 M
|
EV / Sales 2021 |
16,7x |
EV / Sales 2022 |
15,0x |
Nbr of Employees |
1 356 |
Free-Float |
37,3% |
|
|
Duration :
Period :
|
 |
|
Technical analysis trends EQT AB (PUBL)
| Short Term | Mid-Term | Long Term | Trends | Bullish | Bearish | Bearish |
Income Statement Evolution
|
Mean consensus |
OUTPERFORM |
Number of Analysts |
10 |
Last Close Price |
25,17 € |
Average target price |
32,12 € |
Spread / Average Target |
27,6% |
|